Skip to main content

Table 1 Demographic, social, and clinical characteristics of women by HPV genotype result

From: A cross-sectional study of high-risk human papillomavirus clustering and cervical outcomes in HIV-infected women in Rio de Janeiro, Brazil

 

No HPV

Only low risk HPV

One high risk HPV

More than one high risk HPV

Total

N (%)

64 (11.4)

134 (23.8)

183 (32.6)

181 (32.2)

562

Age in years, median (IQR)

37.4 (30.3–41.3)

38.5 (31.1–45.5)

36.0 (29.9–44.0)

32.7 (26.5–41.3)a

35.8 (29.3–43.6)

Non-white race, n (%)

50 (79.4)

99 (73.9)

129 (71.3)

124 (68.9)

402 (72.0)

Years of formal education, median (IQR)

8 (5–11)

8 (5–11)

8 (5–11)

9 (6–11)b

8 (5–11)

Monthly income (US$), median (IQR)

400 (255–600)

425 (250–750)

400 (232.5–750)

450 (232.5–800)

415 (235–750)

Married/living with partner, n (%)

34 (53.1)

85 (63.4)

100 (54.6)

102 (56.4)

321 (57.1)

Age at sexual debut, median (IQR)

16 (14–18)

16 (15–18)

16 (15–18)

16 (15–18)

16 (15–18)

Number of lifetime sexual partners, median (IQR)

5 (4–12)

5 (3–8)

5 (3–10)

5 (3–9)

5 (3–10)

Condom use with last sexual intercourse, n (%)

37 (57.8)

86 (65.7)

117 (65.4)

118 (66.3)

358 (64.9)

HIV-infected current sexual partner, n (%)

9 (14.1)

38 (28.4)c

28 (15.3)

50 (27.6)c, d

125 (22.2)

Number of pregnancies, median (IQR)

2 (1–4)

3 (2–4)

3 (1–4)

2 (1–3)a

2 (1–4)

Current hormonal contraceptive use, n (%)

16 (25.0)

19 (14.3)

27 (14.8)

33 (18.2)

95 (17.0)

Current tobacco usee, n (%)

10 (15.6)

37 (20.6)

36 (20.2)

31 (23.1)

114 (20.5)

Nadir CD4+ lymphocyte countf, median (IQR)

302 (190–570)

307 (155–500)

255 (128–483)

256 (90–414)b

274 (128–467)

CD4+ lymphocyte count at HPV testg, median (IQR)

528 (326–827)

512 (309–679)

433 (309–631)

398 (251–549)a, b

436 (296–679)

HIV RNA <400 copies/mlh, n (%)

27 (42.2)

63 (47.0)

74 (40.4)

62 (34.3)

226 (40.2)

Total months since cART initiation at HPV test, median (IQR)

1.65 (0–12.5)

2.5 (0–15.1)

3.6 (0–16.9)

2.0 (0–13.5)

2.5 (0–14.13)

Total number of low-risk HPV types detected, median (IQR)

0

1 (1–2)

1 (1–2)

2 (1–3)a

1 (0–2)

HPV 16 or 18 detected, n (%)

0

0

42 (23.0)

82 (45.3)d

122 (22.1)

Cytology results, n (%)

     

Any Abnormal

7 (10.9)

22 (16.4)

53 (24.0)c

84 (46.4)c, d

166 (29.5)

ASC-US or AGC

5 (7.8)

14 (10.5)

19 (10.4)

26 (14.4)

64 (11.4)

LSIL

1 (1.6)

7 (5.2)

30 (16.4)c

47 (26.0)c, d

85 (15.1)

HSIL

1 (1.6)

1 (0.8)

4 (2.2)

10 (5.5)

16 (2.9)

Cancer

0

0

0

1 (0.6)

1 (0.2)

  1. aRank sum test of comparison with one HR HPV group p < 0.05
  2. bRank sum test of comparison with no HPV group p < 0.05
  3. cFisher exact test of comparison with no HPV group p < 0.05
  4. dFisher exact test of comparison with one HR HPV group p < 0.05
  5. eThere were 6 women in total missing tobacco use data
  6. fThere were 5 women in total missing CD4+ lymphocyte nadir data
  7. gThere were a total of 37 women with missing CD4+ lymphocyte data at the time of HPV exam
  8. hThere were 63 women with missing HIV RNA data at the time of HPV exam
  9. Abbreviations used
  10. IQR: interquartile range
  11. cART: combination antiretroviral therapy
  12. ASC-US: atypical squamous cells of unknown significance
  13. AGC: atypical glandular cells
  14. LSIL: low-grade squamous intraepithelial lesion
  15. HSIL: high-grade squamous intraepithelial lesion